Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03267303
Recruitment Status : Completed
First Posted : August 30, 2017
Last Update Posted : October 11, 2019
Sponsor:
Information provided by (Responsible Party):
Taisho Pharmaceutical Co., Ltd.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to investigate the efficacy and safety after administration of TS-091 compared with placebo in patients with narcolepsy.

Condition or disease Intervention/treatment Phase
Narcolepsy Drug: TS-091 5mg Drug: TS-091 10mg Drug: Placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Double-blind, Parallel-group Comparative Study 2 of TS-091 in Patients With Narcolepsy
Actual Study Start Date : October 31, 2017
Actual Primary Completion Date : December 13, 2018
Actual Study Completion Date : August 8, 2019

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: TS-091 5mg Drug: TS-091 5mg
Orally taken once daily for 3 weeks
Experimental: TS-091 10mg Drug: TS-091 10mg
Orally taken once daily for 3 weeks
Placebo Comparator: Placebo Drug: Placebo
Orally taken once daily for 3 weeks


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Mean sleep latency in maintenance of wakefulness test [ Time Frame: 3 weeks ]

Secondary Outcome Measures :
  1. Total score on the epworth sleepiness scale [ Time Frame: 3 weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 64 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients diagnosed with narcolepsy type 1 or type 2 based on the International Classification of Sleep Disorders, third edition (ICSD-3) criteria
  2. Patients aged ≥16 to <65 years at the time of obtaining informed consent
  3. Outpatients

Exclusion Criteria:

  1. Patients with sleep disorders other than narcolepsy (e.g., sleep apnea syndrome, periodic limb movement disorder)
  2. Patients with organic brain diseases (including neurodegenerative diseases or cerebrovascular disorders) or epilepsy
  3. Patients with obstructive respiratory diseases (bronchial asthma, emphysema)
  4. Patients with psychiatric disorders (e.g., major depressive disorder, bipolar disorder, schizophrenia)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03267303


Locations
Layout table for location information
Japan
Taisho Pharmaceutical Co., Ltd selected site
Osaka And Other Japanese City, Japan
Korea, Republic of
Taisho Pharmaceutical Co., Ltd selected site
Seoul And Other Korean City, Korea, Republic of
Sponsors and Collaborators
Taisho Pharmaceutical Co., Ltd.
Investigators
Layout table for investigator information
Study Director: Shigeru Okuyama Taisho Pharmaceutical Co., Ltd.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Taisho Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT03267303    
Other Study ID Numbers: TS091-1701
JapicCTI-173689 ( Other Identifier: JapicCTI )
First Posted: August 30, 2017    Key Record Dates
Last Update Posted: October 11, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Taisho Pharmaceutical Co., Ltd.:
Narcolepsy
Additional relevant MeSH terms:
Layout table for MeSH terms
Narcolepsy
Disorders of Excessive Somnolence
Sleep Disorders, Intrinsic
Dyssomnias
 Sleep Wake Disorders
Nervous System Diseases
Mental Disorders